Physician profile
Nathan Toth
NPI 1154867422
$5,745.27
in general payments reported to CMS, 2019-2025
28 companies · $729 in 2025
The $729 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $968 · 2022: $1,054 · 2023: $1,445 · 2024: $1,550 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,659 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,658.52 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $699.78 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $614.52 | 2021-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $501.11 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $492.84 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $402.27 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $377.71 | 2021-2025 | Farxiga, Atacand, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.24 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $349.40 | 2021-2024 | Verquvo |
| Amgen INC. | $316.78 | 2022-2025 | Repatha |
| Novo Nordisk INC | $219.70 | 2024-2025 | Wegovy, Ozempic |
| Edwards Lifesciences Corporation | $192.90 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amarin Pharma, INC. | $174.62 | 2021-2022 | |
| Irhythm Technologies, INC. | $166.96 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Philips North America LLC | $137.59 | 2022-2024 | (5091) Amb Mon & Diag Und |
| Sanofi-Aventis U.S. LLC | $130.07 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicomp INC | $99.61 | 2024 | Telepatch Cardiac Monitor |
| Alnylam Pharmaceuticals INC. | $81.92 | 2025 | Amvuttra |
| Esperion Therapeutics, INC. | $73.28 | 2023-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $64.01 | 2024-2025 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $54.42 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $48.62 | 2023-2025 | |
| Abbott Laboratories | $47.21 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Baxter Healthcare | $32.20 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $30.15 | 2021 | |
| Boston Scientific Corporation | $29.15 | 2024 | Resonate El Icd Vr |
| Arbor Pharmaceuticals, INC. | $16.61 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.41 | 2024 | |
| Karyopharm Therapeutics INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Toth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.